Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Amivantamab plus chemo tied to better outcomes in NSCLC
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.
Amivantamab plus chemo tied to better outcomes in NSCLC
17 Apr 2024
Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.
Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
12 Apr 2024
Maintenance fuzuloparib prolongs survival in ovarian cancer
Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.
